Australia · Delayed Price · Currency is AUD LTR Pharma Statistics
Total Valuation
LTR Pharma has a market cap or net worth of AUD 84.53 million. The enterprise value is 64.86 million.
| Market Cap | 84.53M |
| Enterprise Value | 64.86M |
Important Dates
The next estimated earnings date is Friday, September 11, 2026.
| Earnings Date | Sep 11, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LTR Pharma has 181.78 million shares outstanding. The number of shares has increased by 8.54% in one year.
| Current Share Class | 181.78M |
| Shares Outstanding | 181.78M |
| Shares Change (YoY) | +8.54% |
| Shares Change (QoQ) | +0.40% |
| Owned by Insiders (%) | 5.41% |
| Owned by Institutions (%) | 0.70% |
| Float | 106.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 116.76 |
| PB Ratio | 4.17 |
| P/TBV Ratio | 4.17 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 89.60 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 34.36
| Current Ratio | 34.36 |
| Quick Ratio | 33.10 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -40,091.64 |
Financial Efficiency
Return on equity (ROE) is -54.73% and return on invested capital (ROIC) is -33.79%.
| Return on Equity (ROE) | -54.73% |
| Return on Assets (ROA) | -32.96% |
| Return on Invested Capital (ROIC) | -33.79% |
| Return on Capital Employed (ROCE) | -69.09% |
| Weighted Average Cost of Capital (WACC) | 16.23% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.03 |
| Inventory Turnover | 22.87 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -2.11% in the last 52 weeks. The beta is 2.18, so LTR Pharma's price volatility has been higher than the market average.
| Beta (5Y) | 2.18 |
| 52-Week Price Change | -2.11% |
| 50-Day Moving Average | 0.49 |
| 200-Day Moving Average | 0.48 |
| Relative Strength Index (RSI) | 43.86 |
| Average Volume (20 Days) | 131,314 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, LTR Pharma had revenue of AUD 723,935 and -14.16 million in losses. Loss per share was -0.08.
| Revenue | 723,935 |
| Gross Profit | -5.97M |
| Operating Income | -13.99M |
| Pretax Income | -14.16M |
| Net Income | -14.16M |
| EBITDA | -13.99M |
| EBIT | -13.99M |
| Loss Per Share | -0.08 |
Balance Sheet
The company has 19.66 million in cash and no debt, with a net cash position of 19.66 million or 0.11 per share.
| Cash & Cash Equivalents | 19.66M |
| Total Debt | n/a |
| Net Cash | 19.66M |
| Net Cash Per Share | 0.11 |
| Equity (Book Value) | 20.25M |
| Book Value Per Share | 0.11 |
| Working Capital | 20.07M |
Cash Flow
In the last 12 months, operating cash flow was -10.84 million and capital expenditures -5,946, giving a free cash flow of -10.85 million.
| Operating Cash Flow | -10.84M |
| Capital Expenditures | -5,946 |
| Depreciation & Amortization | 5,772 |
| Net Borrowing | n/a |
| Free Cash Flow | -10.85M |
| FCF Per Share | -0.06 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,932.77% |
| Pretax Margin | -1,956.57% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
LTR Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -8.54% |
| Shareholder Yield | -8.54% |
| Earnings Yield | -16.76% |
| FCF Yield | -12.83% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LTR Pharma has an Altman Z-Score of 83.69 and a Piotroski F-Score of 1.
| Altman Z-Score | 83.69 |
| Piotroski F-Score | 1 |